Skip to main content
SINGULAR HEALTH GROUP LTD logo

SINGULAR HEALTH GROUP LTD — Investor Relations & Filings

Ticker · SHG ISIN · AU0000129892 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 364 across all filing types
Latest filing 2022-11-08 Board/Management Inform…
Country AU Australia
Listing ASX SHG

About SINGULAR HEALTH GROUP LTD

https://singular.health/

Singular Health Group Ltd specializes in the development and commercialization of medical imaging software designed to enhance personalized healthcare. The company’s primary offering, the 3Dicom software suite, employs proprietary volume rendering technology to transform standard 2D DICOM files, such as CT and MRI scans, into immersive 3D visualizations. This platform supports surgical planning, remote clinical collaboration, and patient education by providing interactive anatomical models. Singular Health integrates artificial intelligence to automate image segmentation and diagnostic workflows, facilitating more precise clinical outcomes. Through its 'Scan to Surgery' initiative, the company bridges the gap between diagnostic imaging and physical intervention using virtual reality and 3D printing. Its solutions target medical practitioners, dental professionals, and healthcare institutions globally.

Recent filings

Filing Released Lang Actions
Singular Appoints US-Agent & 3Dicom Partner Program Member 4 pages 721.6KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 9 November 2022 from Singular Health Group Ltd. It details the appointment of a US-based agent and a founding partner for a partner program, focusing on regulatory and commercial developments related to FDA clearance and market entry in the US. There are no financial statements, earnings data, or detailed financial analysis present. The content is primarily a corporate announcement about appointments and partnerships, not a financial report or regulatory filing of financial results. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a call transcript or a legal proceeding update. The document is a corporate announcement about management and partnership changes, which aligns best with the category for Board/Management Information (MANG). The confidence is high given the clear focus on appointments and partnership announcements without financial data.
2022-11-08 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 698.7KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'ACTIVITIES REPORT FOR THE QUARTER – 30 September 2022' dated 31 October 2022. It provides a detailed update on the company's operations, commercialisation strategy, research and development activities, corporate activities, and financial expenditure for the quarter ending 30 September 2022. It includes substantive financial data such as operating expenditure, cash flow, and use of funds comparison. The presence of an Appendix 4C Quarterly cash flow report further confirms this is a comprehensive quarterly report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2022-10-30 English
US FDA 510(k) clearance for 3Dicom MD 2 pages 210.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 27 October 2022 from Singular Health Group Ltd. It announces the FDA 510(k) clearance for their 3Dicom MD software, which is a regulatory approval allowing commercial launch in the US market. The content focuses on the regulatory milestone and commercial implications rather than financial results, management changes, or detailed financial data. The document is relatively short (5082 characters) and serves as a formal announcement of a regulatory clearance event. It does not contain financial statements, earnings data, or detailed management discussion. Therefore, it fits best into the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit into other specific categories.
2022-10-26 English
Notice of Annual General Meeting/Proxy Form 47 pages 807.7KB
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT' and includes details about the time, place, and procedures for the Annual General Meeting (AGM) of Singular Health Group Limited. It contains the agenda items for the AGM, including the adoption of the remuneration report, re-election of a director, and ratification of prior issues of convertible notes and options. The document is a notice and explanatory statement for the AGM, not the actual AGM report or financial statements themselves. It is a formal communication to shareholders about the upcoming meeting and the resolutions to be voted on. Therefore, it fits the category of AGM Information (AGM-R). The document length is substantial (15,000 characters), consistent with detailed AGM notices and explanatory statements. There is no indication that this is a full annual report, audit report, or other filing type. Hence, the classification is AGM-R with high confidence.
2022-10-25 English
Letter to Shareholders 2 pages 142.0KB
AGM Information Classification · 95% confidence The document is a notice regarding the 2022 Annual General Meeting (AGM) of Singular Health Group Ltd. It includes details about the meeting date, location, proxy form instructions, and how shareholders can access the Notice of Meeting and related materials. The document does not contain the actual AGM materials or presentations but rather informs shareholders about the meeting and how to participate. The document length is 2961 characters, which is relatively short and consistent with an announcement or notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), as it provides information about the AGM but is not the full Annual Report or other detailed filings.
2022-10-25 English
SHG signs Research Agreement with AOWA and ECU 3 pages 550.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 1 September 2022 from Singular Health Group Ltd. It details a partnership and research agreement with Arthritis and Osteoporosis WA Foundation and Edith Cowan University for a Healthy Bones and Joints Initiative. The content focuses on the collaboration, funding, project goals, and background information about the involved parties. There are no financial statements, earnings data, management discussion of financial results, or regulatory filings. The document is a corporate announcement about a partnership and research initiative, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2022-08-31 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.